- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Transthyretin amyloid cardiomyopathy (ATTR-CM)
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 1937KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 743KB)
Tafamidis – July 2020
Tafamidis: Capsule 61 mg; Vyndamax® Acalabrutinib: Capsule 100 mg; Calquence®
Last updated
13 November 2020